Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Joel Schrock

Joel Schrock

Director, Portfolio and Decision Analysis

Pfizer

Joel is a Director in Pfizer’s Portfolio and Decision Analysis group, focused on ensuring robust R&D portfolio investment decisions in the late-stage clinical portfolio. Prior joining the Portfolio and Decision Analysis group in 2017, he spent 2 years in Pfizer’s internal consulting group working on efforts to boost R&D productivity. He received a Ph.D. in Pharmacology from Cornell in 2014, with a thesis on the pharmacological characterization of the Sigma1 Receptor and relevant therapeutic applications. He also completed his MBA at Cornell in 2015.

Outside of work, Joel is an avid ultramarathoner and, before becoming a father, a bass guitar player in several cover bands. He now spends most of his free time chasing his toddler, but still finds time for his hobbies, including researching how companies outside the pharmaceutical industry use data to make decisions. He enjoys working with graduate students to help them prepare for the pharmaceutical industry, and is passionate about making connections between academia and business.